Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
- PMID: 19403939
- DOI: 10.1093/annonc/mdp201
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
Comment on
-
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.Ann Oncol. 2009 Feb;20(2):393-4. doi: 10.1093/annonc/mdn729. Ann Oncol. 2009. PMID: 19211503 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
